BML-266 (CAS 96969-83-4)

BML-266, also known as DBeQ, is an investigational compound primarily known for its role as an ATP-competitive inhibitor of the AAA ATPase p97, a key component involved in various cellular processes such as protein degradation, membrane fusion, and the regulation of the ubiquitin-proteasome system. The inhibition mechanism of BML-266 revolves around its ability to bind to the ATPase domain of p97, thereby preventing ATP hydrolysis which is essential for the normal functioning of p97. This disruption can affect multiple cellular pathways, particularly those involved in the handling and clearance of misfolded proteins. In scientific research, BML-266 has been utilized to explore the fundamental biology of cellular processes. For example, studies have used this compound to investigate the role of p97 in the degradation of ubiquitinated proteins and to understand how the inhibition of p97 affects cellular homeostasis and stress responses. Additionally, BML-266 has been instrumental in the study of autophagy and apoptosis, as p97 is involved in the delivery of ubiquitinated proteins to proteasomes and lysosomes for degradation. The compound′s ability to inhibit a critical enzyme like p97 makes it a valuable tool in the study of protein homeostasis and the cellular response to proteotoxic stresses.